
ANI Pharma (ANIP) Stock Forecast & Price Target
ANI Pharma (ANIP) Analyst Ratings
Bulls say
ANI Pharmaceuticals is expected to benefit from increasing volumes in the ACTH gel market, particularly through its products Cortrophin Gel and Acthar Gel, with projected growth continuing into 2025. Financial projections indicate that the company’s adjusted operating margin is anticipated to rise from 25.4% in 2024 to 29.7% by 2028, alongside the generation of over $630 million in operating cash flow during the years 2025-2028. Additionally, upcoming launches and increasing prescription volumes for products like Promethazine Hydrochloride and Dextromethorphan Oral Solution, alongside Prucalopride, are expected to drive revenue growth, leading to revised revenue estimates for FY 2025 upwards to $269.5 million.
Bears say
ANI Pharmaceuticals Inc has reported a significant decline in revenue for its Brands segment during the second and third quarters of 2024, driven by unfavorable market conditions for specific products, notably Cortrophin, which has experienced ongoing pricing pressures. These issues are compounded by anticipated seasonal declines exceeding 30% in the first quarter of 2025 due to Medicare-related challenges and reduced patient access to funding from non-profit organizations. Although the company has exceeded revenue and EBITDA expectations for recent quarters, persistent margin pressures and the evolving market landscape contribute to a fundamentally negative outlook for the stock.
This aggregate rating is based on analysts' research of ANI Pharma and is not a guaranteed prediction by Public.com or investment advice.
ANI Pharma (ANIP) Analyst Forecast & Price Prediction
Start investing in ANI Pharma (ANIP)
Order type
Buy in
Order amount
Est. shares
0 shares